About Forge therapeutics, inc.
Forge Therapeutics, Inc. is a biotechnology company that is dedicated to developing novel antibiotics targeting bacterial metalloenzymes. The company was founded in 2015 and has since been at the forefront of research into new ways of combating antibiotic-resistant bacteria.
The problem of antibiotic resistance has become increasingly urgent in recent years, as more and more strains of bacteria have developed resistance to conventional antibiotics. This has made common medical procedures such as surgery, chemotherapy, and dialysis increasingly risky, as even minor infections can become life-threatening.
Forge Therapeutics is working to address this problem by developing new antibiotics that target bacterial metalloenzymes. These enzymes are essential for the survival of many types of bacteria, making them an attractive target for drug development.
One key advantage of Forge's approach is that it targets a different part of the bacterial cell than traditional antibiotics. This means that even bacteria that have developed resistance to other types of antibiotics may still be vulnerable to Forge's drugs.
The company's lead program is focused on developing a drug called FTI-276, which targets a specific type of metalloenzyme called LpxC. LpxC plays a critical role in the formation of the outer membrane in gram-negative bacteria, which are responsible for many serious infections such as pneumonia and sepsis.
FTI-276 has shown promising results in preclinical studies and is currently undergoing clinical trials. If successful, it could represent a major breakthrough in the fight against antibiotic-resistant infections.
In addition to its work on FTI-276, Forge Therapeutics also has several other programs focused on developing new antibiotics targeting different types of metalloenzymes. These include programs targeting enzymes involved in DNA replication and repair (DnaE), iron acquisition (FetA), and protein synthesis (MnmC).
Overall, Forge Therapeutics represents an exciting new approach to tackling one of the biggest challenges facing modern medicine: antibiotic resistance. With its innovative drug development programs and world-class team of scientists, the company is well-positioned to make a significant impact in this field in the years to come.